- Home
- HFFG vs PBYI Comparison
HFFG vs PBYI Comparison
Compare HFFG & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HFFG | PBYI |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.3M | 263.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HFFG | PBYI |
|---|---|---|
| Price | $2.57 | $5.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 81.1K | ★ 395.4K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | ★ $1,225,541,000.00 | $211,995,000.00 |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $3.35 | N/A |
| P/E Ratio | ★ N/A | $7.62 |
| Revenue Growth | ★ 4.10 | N/A |
| 52 Week Low | $1.70 | $2.58 |
| 52 Week High | $4.93 | $6.12 |
Technical Indicators
Market Signals| Indicator | HFFG | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 54.27 | 57.34 |
| Support Level | $2.52 | $4.84 |
| Resistance Level | $2.68 | $5.92 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 44.87 | 68.47 |
Price Performance
Historical ComparisonAbout HFFG HF Foods Group Inc.
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The company's business consists of one operating segment; HF Group, which operates solely in the United States. The company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.